A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency

Trial Profile

A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs AG 348 (Primary)
  • Indications Haemolytic anaemia
  • Focus Adverse reactions; Proof of concept
  • Acronyms DRIVE PK
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2017 According to Agios Pharmaceuticals media release, updated data from this study will be presented at American Society of Hematology.
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
    • 24 Jun 2017 According to an Agios Pharmaceuticals media release, updated data from the study has been presented at the 22nd Congress of the European Hematology Association (EHA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top